Transplant Co-Morbidity Superpanel
Gene: G6PD
Glucose-6-phosphate dehydrogenase (G6PD) mediates the production of NADPH and Ribose-5-phosphate and is one of the first genes found to be associated with variable drug response. Individuals with G6PD deficiency may have increased risks of adverse reactions to many drugs including primaquine, chloroquine, dapsone, rasburicase, avandaryl tablets (glimepiride + rosiglitazone maleate) and glucovance tablets (metformin + glibenclamide).
https://www.pharmgkb.org/vip/PA166169539Created: 25 Aug 2023, 5:51 a.m. | Last Modified: 25 Aug 2023, 5:51 a.m.
Panel Version: 0.4
Mode of inheritance
X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)
Phenotypes
Hemolytic anemia, G6PD deficient (favism) MIM# 300908
gene: G6PD was added gene: G6PD was added to Transplant Co-Morbidity Superpanel. Sources: Expert Review Green Mode of inheritance for gene: G6PD was set to X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males) Phenotypes for gene: G6PD were set to Haemolytic anaemia